US Patent No: 7,790,856

Number of patents in Portfolio can not be more than 2000

Humanized antibodies that recognize beta amyloid peptide

ALSO PUBLISHED AS: 20070154480

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
JANSSEN ALZHEIMER IMMUNOTHERAPYMADISON, NJ47

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Schenk, Dale B Burlingame, US 122 3390

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (4)
5,227,159 Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies 32 1992
2002/0009,445 Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease 88 2001
2002/0197,258 Compositions and methods for preventing protein aggregation in neurodegenerative diseases 78 2002
2004/0247,612 Immunogenic peptide composition for the prevention and treatment of Alzheimer's Disease 27 2004
 
RAMOT AT TEL-AVIV UNIVERSITY LTD. (2)
5,688,651 Prevention of protein aggregation 93 1994
2005/0152,878 Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases 23 2005
 
BIOCLONES (PROPRIETARY) LIMITED (1)
6,261,569 Retro-, inverso- and retro-inverso synthetic peptide analogues 63 1997
 
SYNTEX (U.S.A.) INC. (1)
5,208,036 N-(.omega., (.omega.-1)-dialkyloxy)- and N-(.omega., (.omega.-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor 135 1990
 
GLAXOSMITHKLINE LLC (3)
5,817,626 Modulators of beta-amyloid peptide aggregation 73 1995
5,854,215 Modulators of .beta.-amyloid peptide aggregation 62 1995
5,854,204 A.beta. peptides that modulate .beta.-amyloid aggregation 107 1996
 
LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY (1)
5,910,427 Antigen non-specific glycosylation inhibiting factor derivatives 13 1996
 
WISCONSIN ALUMNI RESEARCH FOUNDATION (1)
6,022,859 Inhibitors of .beta.-amyloid toxicity 33 1997
 
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (2)
6,165,745 Recombinant production of immunoglobulin-like domains in prokaryotic cells 168 1994
6,277,375 Immunoglobulin-like domains with increased half-lives 233 1997
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (5)
4,912,206 CDNA clone encoding brain amyloid of alzheimer's disease 40 1987
5,472,693 Family of anti-carcinoembryonic antigen chimeric antibodies 36 1993
5,733,548 Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments 33 1995
2003/0068,316 Anti-ADDL antibodies and uses thereof 69 2002
2003/0166,557 SEMA3B inhibits tumor growth and induces apoptosis in cancer cells 23 2002
 
Eli Lilly and Company (10)
5,441,870 Methods for monitoring cellular processing of .beta.-amyloid precursor protein 133 1992
5,766,846 Methods of screening for compounds which inhibit soluble .beta.-amyloid peptide production 134 1993
5,612,486 Transgenic animals harboring APP allele having swedish mutation 139 1993
6,114,133 Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-.beta. peptide (x-.gtoreq.41) 95 1994
5,624,937 Chemical compounds as inhibitors of amyloid beta protein production 81 1995
5,593,846 Methods for the detection of soluble .beta.-amyloid peptide 208 1995
5,605,811 Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein 83 1995
5,721,130 Antibodies and fragments thereof which bind the carboxyl-terminus of an amino-terminal fragment of .beta.APP 98 1995
5,837,672 Methods and compositions for the detection of soluble .beta.-amyloid peptide 109 1995
6,284,221 Method for identifying .beta.-amyloid peptide production inhibitors 75 1996
 
UNIVERSITY OF TENNESSEE RESEARCH CORPORATION, THE (1)
2003/0147,882 METHODS FOR AMYLOID REMOVAL USING ANTI-AMYLOID ANTIBODIES 47 1999
 
NEURALAB LIMITED (1)
2005/0123,544 Prevention and treatment of amyloidogenic disease 37 2004
 
SB2 INC. (2)
5,624,821 Antibodies with altered effector functions 354 1995
5,648,260 DNA encoding antibodies with altered effector functions 289 1995
 
DMS PHARMACEUTICAL INC. (1)
5,231,170 Antibodies to dense microspheres 79 1990
 
BIOSITE INCORPORATED (1)
6,057,098 Polyvalent display libraries 114 1997
 
RASO, VICTOR (3)
6,582,945 Immunological control of .beta.-amyloid levels in vivo 57 2000
2002/0136,718 Immunological control of beta-amyloid levels in vivo 63 2001
2005/0147,613 Immunological control of beta-amyloid levels in vivo 32 2005
 
SUNESIS PHARMACEUTICALS, INC. (1)
2007/0021,454 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease 30 2006
 
ELAN PHARMACEUTICALS, INC. (1)
6,610,493 Screening compounds for the ability to alter the production of amyloid-.beta. peptide 37 1996
 
CREATIVE BIOMOLECULES, INC. (1)
5,258,498 Polypeptide linkers for production of biosynthetic proteins 248 1992
 
SCIOS NOVA INC. (CHANGED TO) (3)
5,220,013 DNA sequence useful for the detection of Alzheimer's disease 75 1989
5,187,153 Methods of treatment using Alzheimer's amyloid polypeptide derivatives 78 1990
5,387,742 Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease 192 1991
 
MERCK SHARP & DOHME CORP. (1)
5,358,708 Stabilization of protein formulations 71 1993
 
SUN HEALTH CORPORATION, INC. (1)
5,192,753 Anti-rheumatoid arthritic drugs in the treatment of dementia 88 1991
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (5)
4,666,829 Polypeptide marker for Alzheimer's disease and its use for diagnosis 263 1985
5,270,165 Method of diagnosis of amyloidoses 79 1991
5,464,823 Mammalian antibiotic peptides 66 1993
5,750,361 Formation and use of prion protein (PRP) complexes 65 1995
6,175,057 Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy 36 1997
 
MILKHAUS LABORATORY, INC. (4)
5,753,624 Materials and methods for treatment of plaquing disease 88 1996
5,798,102 Treatment of cardiomyopathy 27 1997
5,851,996 Materials and methods for treatment of plaquing diseases 93 1998
6,294,171 Methods for treating disease states comprising administration of low levels of antibodies 71 2001
 
AUTOIMMUNE, INC. (4)
5,849,298 Treatment of multiple sclerosis by oral administration of bovine myelin 51 1993
5,869,054 Treatment of multiple sclerosis by oral administration of autoantigens 56 1995
5,733,547 Treatment of autoimmune arthritis by oral administration of type I or type III collagen 54 1995
5,641,473 Treatment of autoimmune diseases by aerosol administration of autoantigens 54 1995
 
UNIVERSITY OF IOWA RESEARCH FOUNDATION (1)
6,339,068 Vectors and methods for immunization or therapeutic protocols 182 1998
 
CELLTECH THERAPEUTICS LIMITED (1)
5,677,425 Recombinant antibody 102 1994
 
THE UNIVERSITY OF BRITISH COLUMBIA (1)
2006/0234,912 Methods for modulating neuronal responses 16 2006
 
MEMORIAL SLOAN-KETTERING CANCER CENTER (1)
6,933,368 Increasing antibody affinity by altering glycosylation of immunoglobulin variable region 67 2002
 
UNIVERSITY OF WASHINGTON (2)
5,958,883 Animal models of human amyloidoses 79 1995
7,195,761 Humanized antibodies that sequester abeta peptide 52 2002
 
CELLTECH LIMITED (1)
4,816,397 Multichain polypeptides or proteins and processes for their production 569 1984
 
FIBROCELL TECHNOLOGIES, INC. (1)
6,432,710 Compositions for regenerating tissue that has deteriorated, and methods for using such compositions 39 2000
 
NEW YORK BLOOD CENTER, INC. (1)
5,620,844 Assays for detecting hepatitis B virus envelope antigens or antibodies thereto and diagnostic test kits for use in performing the assays 22 1993
 
UNIVERSITY OF KANSAS (1)
5,278,049 Recombinant molecule encoding human protease nexin 40 1987
 
BRITISH TECHNOLOGY GROUP LIMITED (1)
5,096,706 Antigen-based treatment for adiposity 27 1986
 
ABBOTT BIOTHERAPEUTICS CORP. (1)
6,210,671 Humanized antibodies reactive with L-selectin 61 1995
 
Genentech, Inc. (14)
4,816,567 Recombinant immunoglobin preparations 1797 1983
5,245,015 Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro 33 1991
5,866,129 Method of producing an antibody with a peptide corresponding to membrane-bound IgA 32 1991
6,407,213 Method for making humanized antibodies 244 1993
5,869,046 Altered polypeptides with increased half-life 104 1995
6,121,022 Altered polypeptides with increased half-life 126 1995
6,054,297 Humanized antibodies and methods for making them 311 1995
5,702,906 Antibodies to neurotrophic factor-4 (NT-4) 29 1995
6,267,958 Protein formulation 187 1996
6,194,551 Polypeptide variants 209 1999
6,528,624 Polypeptide variants 179 1999
6,538,124 Polypeptide variants 152 2000
6,824,780 Anti-tumor antibody compositions and methods of use 77 2000
6,639,055 Method for making humanized antibodies 111 2000
 
The Ohio State University Research Foundation (1)
4,713,366 Antigenic modification of polypeptides 75 1985
 
ABBOTT LABORATORIES (1)
6,015,662 Reagents for use as calibrators and controls 37 1996
 
IMMUNITOR COMPANY LTD. (1)
2003/0092,145 Viral vaccine composition, process, and methods of use 35 2001
 
AVANT IMMUNOTHERAPEUTICS, INC. (1)
6,284,533 Plasmid-based vaccine for treating atherosclerosis 48 1998
 
ABBVIE BIOTHERAPEUTICS INC. (1)
5,622,701 Cross-reacting monoclonal antibodies specific for E- and P-selectin 63 1994
 
THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (1)
5,262,332 Diagnostic method for Alzheimer's disease: examination of non-neural tissue 60 1989
 
N.V. Innogenetics S.A. (1)
2004/0265,919 Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease 39 2004
 
BAYER PHARMACEUTICALS CORPORATION (1)
5,786,180 Monoclonal antibody 369.2B specific for .beta. A4 peptide 74 1995
 
EPIMMUNE INC. (1)
5,736,142 Alteration of immune response using pan DR-binding peptides 79 1994
 
T C U.S.A. INC. (1)
6,787,129 Castor polyester as gloss agents in anionic systems 18 2003
 
PROTEIN DESIGN LABS, INC. (5)
* 5,530,101 Humanized immunoglobulins 920 1990
5,585,089 Humanized immunoglobulins 955 1995
5,693,761 Polynucleotides encoding improved humanized immunoglobulins 418 1995
5,693,762 Humanized immunoglobulins 761 1995
6,180,370 Humanized immunoglobulins and methods of making the same 501 1995
 
UCB PHARMA S.A. (2)
2005/0123,534 Humanised antibodies 24 2004
2005/0136,054 Humanised antibodies 23 2004
 
MEDICAL RESEARCH COUNCIL (1)
5,225,539 Recombinant altered antibodies and methods of making altered antibodies 673 1991
 
Cytrx Corporation (1)
5,824,322 Compositions and methods for growth promotion 57 1996
 
ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (1)
5,994,083 Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable 26 1995
 
REGENTS OF THE UNIVERSITY OF MINNESOTA (3)
5,837,473 Methods of screening for agents affecting the deposition of .beta.-amyloid peptides on amyloid plaques in human tissue 53 1995
5,877,399 Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease 120 1996
6,262,335 Transgenic mice expressing APP mutant at amino acids 717, 721 and 722 56 1998
 
CEDARS-SINAI MEDICAL CENTER (1)
5,679,348 Immunotherapy for recurrent HSV infections 51 1992
 
CELLTECH R&D LTD. (2)
5,859,205 Humanised antibodies 353 1994
6,632,927 Humanized antibodies 215 2001
 
NEOTOPE BIOSCIENCES LIMITED (1)
6,923,964 Active immunization of AScr for prion disorders 35 2000
 
INTELLECT NEUROSCIENCES INC. (1)
2003/0073,655 Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof 72 2002
 
WYETH (2)
2006/0099,206 Methods and compositions for improving recombinant protein production 24 2005
2006/0210,557 Stabilized liquid polypeptide formulations 33 2006
 
NATIONAL RESEARCH COUNCIL OF CANADA (1)
5,773,007 Vaccine compositions 29 1994
 
NIHON UNIVERSITY (1)
6,962,984 IgA nephropathy-related DNA 23 2000
 
AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (1)
2006/0182,321 Method and apparatus for extracting third ventricle information 20 2004
 
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (1)
5,589,154 Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease 75 1994
 
BTG INTERNATIONAL LIMITED (1)
6,548,640 Altered antibodies 115 1995
 
WYETH LLC (27)
7,189,819 Humanized antibodies that recognize beta amyloid peptide 39 2001
7,582,733 Humanized antibodies that recognize beta amyloid peptide 18 2002
2005/0009,150 Humanized antibodies that recognize beta amyloid peptide 23 2002
7,179,892 Humanized antibodies that recognize beta amyloid peptide 60 2003
7,256,273 Humanized antibodies that recognize beta amyloid peptide 48 2003
2004/0171,815 Humanized antibodies that recognize beta amyloid peptide 36 2003
2004/0171,816 Humanized antibodies that recognize beta amyloid peptide 30 2003
2006/0188,512 Active immunization to generate antibodies to solble a-beta 21 2004
2004/0213,800 Active immunization to generate antibodies to soluble A-beta 33 2004
2005/0249,725 Humanized antibodies that recognize beta amyloid peptide 38 2004
2005/0118,651 Humanized antibodies that recognize beta amyloid peptide 42 2004
2007/0134,762 Immunogenic peptide carrier conjugates and methods of producing same 28 2004
2007/0161,088 Beta immunogenic peptide carrier conjugates and methods of producing same 28 2004
2006/0160,161 Methods for assessing antibodies to neurodegenerative disease-associated antigens 32 2005
2006/0153,772 Contextual fear conditioning for predicting immunotherapeutic efficacy 22 2005
2006/0165,682 Humanized antibodies that recognize beta amyloid peptide 29 2005
2006/0198,851 Humanized Abeta antibodies for use in improving cognition 37 2005
2006/0240,486 Immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies 29 2005
2006/0257,396 Abeta antibodies for use in improving cognition 38 2005
2006/0193,850 Anti a beta antibody formulation 39 2006
2006/0280,743 Humanized antibodies that recognize beta amyloid peptide 31 2006
2007/0072,307 Methods of purifying Fc region containing proteins 31 2006
2007/0082,367 Methods of purifying anti a beta antibodies 24 2006
2008/0050,367 Humanized antibodies that recognize beta amyloid peptide 24 2006
2007/0238,154 Humanized antibodies that recognize beta-amyloid peptide 23 2007
2008/0145,373 A-BETA IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME 27 2007
2009/0142,270 PREVENTION AND TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY 20 2008
 
LILLY AND COMPANY (1)
2004/0241,164 Use of antibodies having high affinity for soluble ab to treat conditions and diseases related to ass 47 2004
 
NOVARTIS AG (1)
2004/0197,324 High concentration antibody and protein formulations 75 2004
 
WYETH HOLDINGS CORPORATION (2)
5,723,130 Adjuvants for vaccines against respiratory syncytial virus 43 1996
6,399,314 Methods of detection of amyloidogenic proteins 53 1999
 
TAKEDA PHARMACEUTICAL COMPANY LIMITED (2)
5,750,349 Antibodies to .beta.-amyloids or their derivatives and use thereof 130 1994
5,955,317 Antibodies to .beta.-amyloids or their derivatives and use thereof 89 1997
 
THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (2)
5,585,100 Dual carrier immunogenic construct 74 1995
5,955,079 Dual carrier immunogenic construct 62 1995
 
BRONSON NUTRITIONALS, LLC (5)
5,869,093 Treatment of immune diseases by oral administration of autoantigens 65 1994
5,645,820 Treatment of autoimmune diseases by aerosol administration of autoantigens 62 1995
5,571,499 Treatment of autoimmune diseases by aerosol administration of autoantigens 77 1995
5,571,500 Treatment of autoimmune diseases through administration by inhalation of autoantigens 63 1995
5,641,474 Prevention of autoimmune diseases by aerosol administration of autoantigens 60 1995
 
JANSSEN SCIENCES IRELAND UC (2)
6,913,745 Passive immunization of Alzheimer's disease 58 2000
2009/0069,544 HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID PEPTIDE 15 2007
 
PRAECIS PHARMACEUTICALS INCORPORATED (3)
6,303,567 Modulators of .beta.-amyloid peptide aggregation comprising D-amino acids 77 1996
5,985,242 Modulators of .beta.-amyloid peptide aggregation comprising D-amino acids 62 1997
2002/0133,001 Therapeutic agents and methods of use thereof for treating an amyloidogenic disease 45 2001
 
JANSSEN ALZHEIMER IMMUNOTHERAPY (47)
6,787,523 Prevention and treatment of amyloidogenic disease 70 1998
* 6,761,888 Passive immunization treatment of Alzheimer's disease 85 2000
6,710,226 Transgenic mouse assay to determine the effect of A.beta. antibodies and A.beta. Fragments on alzheimer's disease characteristics 59 2000
* 6,743,427 Prevention and treatment of amyloidogenic disease 110 2000
6,750,324 Humanized and chimeric N-terminal amyloid beta-antibodies 66 2000
6,787,138 Prevention and treatment of amyloidogenic disease 59 2000
6,787,139 Prevention and treatment of amyloidogenic disease 56 2000
6,787,140 Prevention and treatment of amyloidogenic disease 57 2000
6,787,143 Prevention and treatment of amyloidogenic disease 50 2000
6,787,144 Prevention and treatment of amyloidogenic disease 59 2000
* 6,787,637 N-Terminal amyloid-.beta. antibodies 70 2000
6,875,434 Methods of treatment of Alzheimer's disease 59 2000
6,890,535 Pharmaceutical compositions and methods for treatment of amyloid diseases 47 2000
6,905,686 Active immunization for treatment of alzheimer's disease 50 2000
2004/0081,657 Prevention and treatment of amyloidogenic disease 44 2003
2005/0059,802 Prevention and treatment of amyloidogenic disease 38 2004
2004/0265,308 Prevention and treatment of amyloidogenic disease 45 2004
6,808,712 Prevention and treatment of amyloidogenic disease 34 2004
6,818,218 Prevention and treatment of amyloidogenic disease 37 2004
* 6,866,849 Prevention and treatment of amyloidogenic disease 58 2004
* 6,866,850 Prevention and treatment of amyloidogenic disease 55 2004
6,982,084 Prevention and treatment of amyloidogenic disease 35 2004
7,014,855 Prevention and treatment of amyloidogenic disease 48 2004
2005/0019,328 Prevention and treatment of amyloidogenic disease 35 2004
2005/0059,591 Prevention and treatment of amyloidogenic disease 35 2004
2004/0219,146 Prevention and treatment of amyloidogenic disease 31 2004
6,962,707 Prevention and treatment of amyloidogenic disease 40 2004
2004/0247,591 Prevention and treatment of amyloidogenic disease 22 2004
2004/0265,301 Prevention and treatment of amyloidogenic disease 26 2004
2005/0158,304 Prevention and treatment of amyloidogenic disease 24 2004
2004/0247,590 Prevention and treatment of amyloidogenic disease 25 2004
2005/0013,815 Prevention and treatment of amyloidogenic disease 34 2004
2005/0019,330 Prevention and treatment of amyloidogenic disease 57 2004
2005/0048,049 Prevention and treatment of amyloidogenic disease 36 2004
2005/0191,292 Prevention and treatment of amyloidogenic disease 24 2004
2005/0249,727 Prevention and treatment of amyloidogenic disease 36 2004
2005/0196,399 Prevention and treatment of amyloidogenic disease 25 2004
6,946,135 Prevention and treatment of amyloidogenic disease 41 2004
6,972,127 Prevention and treatment of amyloidogenic disease 55 2004
2005/0163,788 Prevention and treatment of amyloidogenic disease 35 2004
2005/0255,122 Prevention and treatment of amyloidogenic disease 35 2004
2005/0142,132 Prevention and treatment of amyloidogenic disease 38 2005
2005/0191,314 Prevention and treatment of amyloidogenic disease 34 2005
2006/0029,611 Prevention and treatment of amyloidogenic disease 33 2005
2006/0034,858 Prevention and treatment of amyloidogenic disease 33 2005
2007/0154,480 Humanized antibodies that recognize beta amyloid peptide 28 2006
2008/0096,818 PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE 34 2007
 
AMERSHAM PLC (1)
2003/0135,035 Human ZZAP1 protein 23 2002
 
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (1)
6,417,178 Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits 76 1997
 
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (1)
5,858,981 Method of inhibiting phagocytosis 43 1996
 
Mindset Biopharmaceuticals (USA) (1)
2002/0086,847 Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof 78 2001
 
BAYER CORPORATION (1)
2002/0160,394 Regulation of transthyretin to treat obesity 58 2002
 
RINAT NEUROSCIENCE CORPORATION (1)
2006/0057,701 Antibodies directed against amyloid-beta peptide and methods using same 38 2005
 
GENETICS INSTITUTE, LLC (5)
5,385,887 Formulations for delivery of osteogenic proteins 170 1993
6,270,757 Formulations for IL-11 27 1994
6,372,716 Formulations for factor IX 25 1994
5,770,700 Liquid factor IX formulations 48 1996
5,744,132 Formulations for IL-12 37 1997
 
ANDRULIS PHARMACEUTICALS CORPORATION (1)
5,434,170 Method for treating neurocognitive disorders 92 1993
 
XOMA TECHNOLOGY LTD. (2)
5,618,920 Modular assembly of antibody genes, antibodies prepared thereby and use 154 1994
5,576,184 Production of chimeric mouse-human antibodies with specificity to human tumor antigens 119 1994
 
UNIVERSITY OF SASKATCHEWAN (1)
5,837,268 GnRH-leukotoxin chimeras 30 1996
 
Antigenics, Inc. (2)
5,057,540 Saponin adjuvant 190 1990
5,583,112 Saponin-antigen conjugates and the use thereof 92 1992
 
ZOETIS SERVICES LLC (1)
5,989,566 Stable vaccine compositions for parenteral administration, a method for their use, and a process for their preparation 53 1996
 
The Scripps Research Institute (3)
4,879,213 Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse 204 1986
5,846,533 Antibodies specific for native PrP.sup.Sc 78 1996
6,562,341 Antibodies specific for native PrPSc 35 2001
 
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2)
4,883,666 Controlled drug delivery system for treatment of neural disorders 220 1987
5,891,991 Amyloid precursor-like protein and uses thereof 36 1996
 
HUNTINGTON POTTER (1)
5,780,587 Compounds and methods for inhibiting .beta.-protein filament formation and neurotoxicity 79 1995
 
UNIVERSITY OF ROCHESTER (1)
5,231,000 Antibodies to A4 amyloid peptide 117 1991
 
MCW RESEARCH FOUNDATION, INC. (1)
6,057,367 Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses 83 1997
 
Alteon Inc. (1)
5,935,927 Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts 77 1996
 
MORPHOSYS AG (1)
2005/0169,925 Anti-amyloid beta antibodies and their use 43 2005
 
CITY OF HOPE (2)
5,652,334 Method for design of substances that enhance memory and improve the quality of life 30 1993
5,470,951 Peptides for antagonizing the effects of amyloid .beta.protein 44 1993
 
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (1)
6,150,091 Direct molecular diagnosis of Friedreich ataxia 53 1996
 
PARDRIDGE, WILLIAM (1)
5,004,697 Cationized antibodies for delivery through the blood-brain barrier 91 1987
 
NEW YORK UNIVERSITY (2)
6,713,450 Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid .beta. for induction of an immune response to amyloid .beta. and amyloid deposits 45 2001
2003/0166,558 Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha-synuclein, or polyglutamine repeats for induction of an immune response thereto 54 2002
 
Morphosys Gesellschaft fur Proteinoptimerung mbH (1)
5,514,548 Method for in vivo selection of ligand-binding proteins 92 1994
 
MILLENNIUM PHARMACEUTICALS, INC. (2)
7,147,851 Humanized immunoglobulin reactive with .alpha.4.beta.7 integrin 32 1996
6,727,349 Recombinant anti-CCR2 antibodies and methods of use therefor 26 2000
 
THE GENERAL HOSPITAL CORPORATION (1)
2003/0009,104 In vivo multiphoton diagnostic detection and imaging of a neurodegenerative disease 16 2001
 
THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (2)
5,744,368 Methods for the detection of soluble amyloid .beta.-protein (.beta.AP) or soluble transthyretin (TTR) 64 1993
7,112,661 Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha 19 1999
 
NEUROCHEM (INTERNATIONAL) LIMITED (2)
6,331,440 Peptide binding the KLVFF-sequence of amyloid-.beta. 38 1998
2002/0094,335 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases 71 2001
 
AMGEN INC. (1)
5,731,284 Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product 38 1995
 
SMITHKLINE BEECHAM CORPORATION (1)
6,936,698 Monoclonal antibodies with reduced immunogenicity 37 2001
 
GLAXOSMITHKLINE BIOLOGICALS SA (1)
5,776,468 Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A 82 1996
 
PRESIDENT AND FELLOWS OF HARVARD COLLEGE (1)
5,601,827 Diphtheria toxin vaccines 37 1995
 
UNIVERSITY OF SOUTHERN CALIFORNIA (1)
6,218,506 Amyloid .beta. protein (globular assembly and uses thereof) 84 1997
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
JANSSEN SCIENCES IRELAND UC (1)
9,051,363 Humanized antibodies that recognize beta amyloid peptide 0 2007
 
WYETH LLC (5)
8,916,165 Humanized Aβ antibodies for use in improving cognition 0 2005
8,613,920 Treatment of amyloidogenic diseases 0 2007
8,784,810 Treatment of amyloidogenic diseases 0 2008
9,067,981 Hybrid amyloid-beta antibodies 0 2009
8,440,799 Methods of purifying anti A β antibodies 0 2010
 
JANSSEN ALZHEIMER IMMUNOTHERAPY (2)
8,535,673 Prevention and treatment of amyloidogenic disease 0 2004
8,642,044 Prevention and treatment of amyloidogenic disease 0 2007
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Mar 7, 2018
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 7, 2022
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00